The Discovery
Chapter 1
In the 1970s, doctors faced a tough choice.
Key moment
In the 1970s, doctors faced a tough choice.
In the 1970s, doctors faced a tough choice. Men with prostate cancer needed their testosterone shut down. Women with endometriosis suffered from painful tissue growing in the wrong places, fed by estrogen. The only answers were surgery, radiation, or strong medicines with awful side effects. Scientists asked: could we use the body's own hormone system against these diseases? The answer was hidden in the pituitary gland.
The Breakthrough
Chapter 2
Researchers discovered that GnRH is the master control hormone.
Key moment
Researchers discovered that GnRH is the master control hormone.
Researchers discovered that GnRH is the master control hormone. It's a tiny string of amino acids that tells your pituitary gland to release two other hormones: LH and FSH. These hormones then tell your ovaries and testes to make sex hormones. Hoechst scientists realized they could make an artificial version of GnRH that would be super-potent. When you used it over and over, the body's sensors would get tired and shut down the whole system.
The Trials
Chapter 3
Hoechst called their discovery HOE-766, later named buserelin.
Key moment
Hoechst called their discovery HOE-766, later named buserelin.
Hoechst called their discovery HOE-766, later named buserelin. They tested it in cancer patients first. The results were surprising and powerful. Men with prostate cancer who received buserelin had the same hormone shutdown as men who had their testicles surgically removed. Women with endometriosis finally got relief. By 1982, the drug was approved in Germany. By the late 1980s, doctors all over Europe were using it.
The Crisis
Chapter 4
Then came an unexpected discovery.
Key moment
Then came an unexpected discovery.
Then came an unexpected discovery. Doctors realized that buserelin could help couples trying to have babies through IVF. By shutting down natural hormone release at just the right time, they could control exactly when eggs grew and were released. This meant women could take hormone shots that made many eggs ready at once, instead of just one per month. Buserelin became a key part of IVF protocols worldwide.
The Legacy
Chapter 5
Today, buserelin remains important for cancer treatment, endometriosis, and fertility help.
Key moment
It proved that the body's own hormone system could be turned into a powerful medicine.
Today, buserelin remains important for cancer treatment, endometriosis, and fertility help. Scientists learned from buserelin's success and created even better drugs. But buserelin showed them the way. It proved that the body's own hormone system could be turned into a powerful medicine. Now sold as Suprefact across Europe and Asia, it helps thousands of patients every year find relief from serious diseases and achieve their dream of having children.
Peptide history · 1982
Buserelin Acetate
The first GnRH agonist that taught doctors how to turn off hormone signals to fight cancer and help couples have babies
Buserelin is a man-made copy of a natural hormone that controls sex hormones in your body. It was one of the first drugs in its class, developed by Hoechst in the 1980s. Doctors use it to treat prostate cancer, endometriosis, and to help with IVF by controlling when eggs are released. It works by first giving a big signal to your pituitary gland, then turning off the hormone response completely.
When this peptide was first identified
Compound classification
Current regulatory status
Main area of investigation
How this peptide is typically given
Molecular structure type
Hoechst AG
Developer and manufacturer · Hoechst AG (now Sanofi), Frankfurt, Germany
Created buserelin as HOE-766 in the early 1980s
Jürg Stucki
Research scientist · Hoechst AG Research Division, Frankfurt, Germany
Key researcher in GnRH agonist development at Hoechst
Sanofi-Aventis
Current manufacturer · Sanofi-Aventis (now Sanofi), Paris, France
Now produces Suprefact worldwide after Hoechst merger
Roger Sandow
Pharmacology researcher · Hoechst AG Endocrinology Division, Germany
Published comprehensive review of buserelin's effects in 1990
15 milestones, 1977 – 2025.
- 1977GnRH hormone structure fully understood by scientists
- 1979Hoechst begins development of buserelin as HOE-766
- 1982Buserelin approved in Germany as Suprefact
- 1983First clinical studies show success in prostate cancer patients
- 1985Approval in UK and other European countries
- 1987Doctors discover usefulness in endometriosis treatment
- 1988IVF programs begin using buserelin for cycle control
- 1990Comprehensive research review published in medical journals
- 1995Approval in Japan and other Asian countries
- 2000Buserelin nasal spray and injection forms both widely available
- 2005Over 20 years of safety data compiled from millions of patients
- 2015Still one of the most used GnRH agonists worldwide
- 2020Continues as first-line treatment for multiple conditions
- 2023Remains approved and used across Europe and Asia
- 2025Buserelin teaches new generations of doctors about hormone control
Buserelin works through a clever trick that takes advantage of how your body learns. Your pituitary gland has sensors that listen for the hormone GnRH. When it hears the signal, it releases two other hormones called LH and FSH. These hormones tell your reproductive organs to make sex hormones. Buserelin is a fake GnRH that your pituitary cannot ignore. At first, it makes the pituitary work overtime. But after a few days, the pituitary gets tired. Its sensors stop responding. The release of LH and FSH drops to almost zero. Sex hormone production crashes. This is called desensitization. It's temporary. When you stop taking buserelin, your pituitary wakes back up.
Molecular structure
- Chemical Name
- Buserelin is a nine-amino-acid peptide (a short chain of amino acids)
- Molecular Weight
- 1239.4 grams per mole
- How It's Different From GnRH
- Buserelin has changes at two positions that make it ten times stronger and longer-lasting than natural GnRH
- Chemical Formula
- C60H86N16O13 (contains carbon, hydrogen, nitrogen, and oxygen atoms)
Year buserelin was first approved in Germany
Safe clinical use in millions of patients worldwide
Cancer treatment, endometriosis relief, and fertility help
Effectiveness rate in suppressing sex hormones when used correctly
Real stories, real lives
Elena
David
The future of Buserelin
- Combination therapy development - scientists are testing buserelin combined with other drugs to work even better against cancer while causing fewer side effectsResearch Stage
- New delivery methods - researchers are creating long-acting depot formulations that last months instead of days, making treatment easier for patientsResearch Stage
- Personalized treatment - doctors are learning to predict which patients will respond best to buserelin before treatment starts, using genetic testingResearch Stage
- Extended use studies - ongoing research into long-term safety to help doctors decide the best treatment lengths for different conditionsResearch Stage
Be inspired
The story of Buserelin is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.